Nanoparticle-based drug delivery to the vagina: A review

Research output: Contribution to journalReview article

Abstract

Vaginal drug administration can improve prophylaxis and treatment of many conditions affecting the female reproductive tract, including sexually transmitted diseases, fungal and bacterial infections, and cancer. However, achieving sustained local drug concentrations in the vagina can be challenging, due to the high permeability of the vaginal epithelium and expulsion of conventional soluble drug dosage forms. Nanoparticle-based drug delivery platforms have received considerable attention for vaginal drug delivery, as nanoparticles can provide sustained release, cellular targeting, and even intrinsic antimicrobial or adjuvant properties that can improve the potency and/or efficacy of prophylactic and therapeutic modalities. Here, we review the use of polymeric nanoparticles, liposomes, dendrimers, and inorganic nanoparticles for vaginal drug delivery. Although most of the work toward nanoparticle-based drug delivery in the vagina has been focused on HIV prevention, strategies for treatment and prevention of other sexually transmitted infections, treatment for reproductive tract cancer, and treatment of fungal and bacterial infections are also highlighted.

Original languageEnglish (US)
Pages (from-to)500-514
Number of pages15
JournalJournal of Controlled Release
Volume190
DOIs
StatePublished - Sep 28 2014

    Fingerprint

Keywords

  • Cervical cancer
  • HIV PrEP
  • Microbicides
  • Mucosal vaccines
  • Sexually transmitted infections

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this